arrow
C

Christina Yau

University of Gothenburg
H指数:92
被引数:7.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

循环肿瘤DNA细化新辅助治疗耐药乳腺肿瘤的危险分层

2025-12-090
OAAI
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial

孕酮受体(PR)在绝经前乳腺癌中的肿瘤内异质性:一项随机试验的二次分析

2025-10-010
OAAI
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

ASO视觉摘要:新辅助化疗后至手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-290
PRE
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

新辅助化疗后手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-230
PRE
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

ASO视觉摘要:新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化率的影响:根据I-SPY2临床试验中分子高风险肿瘤的组织学亚型进行分析

2025-08-230
PRE
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化影响的评估:基于I-SPY2临床试验中按组织学亚型分析分子高风险肿瘤

2025-07-240
OA
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

在多中心新辅助I-SPY2试验中,基于自我识别种族的腋窝手术管理差异

2025-07-230
OA
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
2025-02-130
OA
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial
2025-02-130
PRE
Pathologic complete response (pCR) rates for patients with HRD/HER2L high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在I-SPY2临床试验中,根据临床和分子特征,HRD/HER2L高风险早期乳腺癌(EBC)患者的病理完全缓解(pCR)率。

2025-02-012
PRE
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets

使用紧凑特征集对非TCGA癌症样本进行TCGA分子亚型分类

2025-02-014
OAAI
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
2024-12-030
OAAI
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
2024-11-010
OAAI
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-141
PRE
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-144
PRE
ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
2024-08-130
PRE
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
2024-07-121
OAAI